Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

(2017) Riccardo Lencioni et al.   JOURNAL OF HEPATOLOGY

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

(2017) Tim Meyer et al.   LIVER INTERNATIONAL

Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization

(2015) Beom Kyung Kim et al.   DIGESTIVE AND LIVER DISEASE

Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma

(2015) Olivio F. Donati et al.   EUROPEAN RADIOLOGY

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

(2015) Adeel R. Seyal et al.   HEPATOLOGY

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

(2014) Sangheun Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment

(2014) Mi Na Kim et al.   Expert Review of Gastroenterology & Hepatology

Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization

(2012) B. K. Kim et al.   CLINICAL CANCER RESEARCH

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

(2012) Yozo Sato et al.   UPSALA JOURNAL OF MEDICAL SCIENCES

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

(2011) Julien Edeline et al.   CANCER

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma

(2011) Ju Hyun Shim et al.   JOURNAL OF HEPATOLOGY

Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models

(2011) Ju Hyun Shim et al.   RADIOLOGY

Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma

(2010) Ahsun Riaz   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation

(2010) Ahsun Riaz et al.   JOURNAL OF HEPATOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute